---
title: "\"DINGDANG HEALTH\" narrowed its annual loss to 49.02 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280041015.md"
description: "DINGDANG HEALTH announced its 2025 annual performance, with revenue recorded at 4.888 billion RMB, an increase of 4.7% year-on-year. The loss narrowed from 376 million RMB in the previous year to 49.02 million RMB, with a loss per share of 0.04 RMB. No final dividend will be distributed"
datetime: "2026-03-22T05:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280041015.md)
  - [en](https://longbridge.com/en/news/280041015.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280041015.md)
---

# "DINGDANG HEALTH" narrowed its annual loss to 49.02 million RMB

DINGDANG HEALTH (09886.HK) announced its 2025 annual results, with revenue reaching 4.888 billion RMB, an increase of 4.7% year-on-year. The loss narrowed from 376 million RMB in the previous year to 49.02 million RMB, with a loss per share of 0.04 RMB. No final dividend is declared

### Related Stocks

- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [09886.HK](https://longbridge.com/en/quote/09886.HK.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [516610.CN](https://longbridge.com/en/quote/516610.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Upsher-Smith launches Restasis generic cyclosporine ophthalmic emulsion 0.05%](https://longbridge.com/en/news/287079790.md)
- [JD Health files HKEX return disclosing share buyback at HKD 40.3 each](https://longbridge.com/en/news/287057883.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)